Risk of Rapid Kidney Function Decline, All-Cause Mortality, and Major Cardiovascular Events in Nonalbuminuric Chronic Kidney Disease in Type 2 Diabetes
Oyunchimeg Buyadaa, Dianna J Magliano, Agus Salim, Digsu N Koye, Jonathan E Shaw
Diabetes Care | AMER DIABETES ASSOC | Published : 2020
OBJECTIVE: We aimed to investigate the rate of progression of nonalbuminuric chronic kidney disease (CKD) to end-stage kidney disease (ESKD) or death or major cardiovascular events (MACE) compared with albuminuric and nonalbuminuric phenotypes. RESEARCH DESIGN AND METHODS: We included 10,185 participants with type 2 diabetes enrolled in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. Based on baseline albuminuria and estimated glomerular filtration rate (eGFR), participants were classified as having no kidney disease (no CKD), albuminuria only (albuminuric non-CKD), reduced eGFR only (nonalbuminuric CKD), or both albuminuria and reduced eGFR (albuminuric CKD). The rate ..View full abstract
The ACCORD study was conducted by the ACCORD study investigators and supported by the NHLBI, by other components of the National Institutes of Health, including the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Eye Institute, by the Centers for Disease Control and Prevention, and by General Clinical Research Centers. Data from ACCORD and ACCORDION studies reported in this article were obtained from the NHLBI BioLINCC. O.B. is supported by a Monash University Postgraduate Research Scholarship and a Baker Bright Sparks Scholarship. D.J.M. and J.E.S. are supported by National Health and Medical Research Council Senior Research Fellowships. This work is partially supported by the Victorian Government's Operational Infrastructure Support Program.